2 completed, 2 unknown, 1 not yet recruiting. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Unknown 2, Not yet recruiting 1 |
Follow Hypertension,Essential: new trials by email Literature Review of Hypertension,Essential trials Research Report on Hypertension,Essential
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR) Dehydrated Alcohol Injection, USP, Sham procedure - Hypertension, Hypertension,Essential | Phase 3 | Not yet recruiting | Ablative Solutions, Inc. | 202 | 2026-10-01 | 2026-08-20 |
| Phase III Study to Evaluate the Efficacy and Safety of AD-209 AD-209, AD-2091, AD-209 Placebo - Hypertension,Essential | Phase 3 | Unknown | Addpharma Inc. | 280 | 2024-05-20 | 2024-05-21 |
| A Study to Evaluate the Efficacy and Safety of AD-224 AD-224A, AD-224B, AD-224C - Hypertension,Essential | Phase 3 | Completed | Addpharma Inc. | 254 | 2024-04-15 | 2026-08-03 |
| A Study to Evaluate the Efficacy and Safety of AD-223 AD-223A, AD-223B, AD-223C - Hypertension,Essential | Phase 3 | Completed | Addpharma Inc. | 502 | 2024-02-15 | 2025-04-04 |
| Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension. fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg, Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) - Hypertension, Hypertension,Essential | Phase 3 | Unknown | Brainfarma Industria Química e Farmacêutica S/A | 400 | 2022-08-01 | 2022-03-21 |
Essential Hypertension (5) · Hypertension (2)
Cardiovascular Diseases (5) · Vascular Diseases (5) · Hypertension (3)
Ethanol (1) · Indapamide (1) · olmesartan (1)
Addpharma Inc. (3) · Ablative Solutions, Inc. (1) · Brainfarma Industria Química e Farmacêutica S/A (1)
South Korea (3) · United States (1)
Atul Pathak, Prof. (1) · Chang Gyu Park, M.D., Ph.D (1) · David Kandzari, MD (1) · Felix Mahfoud, Prof.Dr. med (1) · Gregg Stone, MD (1) · InHo Chae, M.D., Ph.D (1) · Jin Ho Shin, M.D., Ph.D (1) · Michael Weber, MD (1)